Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kunxian Capsule is a **traditional Chinese patent medicine** formulated from four herbal components: Tripterygium hypoglaucum (H.Lév.) Hutch, Epimedium brevicornu Maxim, Cuscuta chinensis Lam, and Lycium barbarum L. Its main indications include **rheumatoid arthritis, nephrotic syndrome, systemic lupus erythematosus, Henoch-Schönlein purpura, IgA nephropathy, ankylosing spondylitis, psoriatic arthritis**, and other autoimmune or inflammatory diseases. Pharmacologically, Kunxian Capsule is recognized for its immunomodulatory and anti-inflammatory actions. Mechanistically, it acts primarily by inhibiting inflammatory networks, modulating PI3K/AKT/mTOR and β-catenin signaling pathways, and suppressing immune cell activation and chemokine production. The key active constituents include terpenoids (e.g., triptolide, celastrol), sesquiterpene pyridines (e.g., wilforgine, wilforine), and flavonoids (e.g., icariin, epimedin A/B/C) derived from its herbal components[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kunxian Capsule.